Our drug discovery platforms
At MIPS we deploy significant research infrastructure and experience to support internal drug discovery programs. This infrastructure is arranged into a series of research platforms that are also available to external partners to help progress their projects. The platforms are part of a broader network of Monash Technology Research Platforms and can be accessed externally via a range of models of interaction from collaboration through to fee-for-service.
Monash Fragment Platform: The Monash Fragment Platform (MFP) designs and runs fragment-based drug discovery (FBDD) campaigns for new therapeutic targets. FBDD screening uses a high-quality, in-house fragment library designed to maximise chemical space coverage and enable rapid hit optimisation. Screening cascades are tailored and use a variety of physical techniques such as NMR and Surface Plasmon Residence (SPR). Bespoke medicinal chemistry support subsequently facilitates Rapid Elaboration of Fragments into Leads (REFIL), to power translation.
Monash Proteomics and Metabolomics: The MPMF’s Parkville node provides cutting edge metabolomics, lipidomics and proteomics capabilities for MIPS researchers and the wider research community. Our analytical methods are suitable for samples arising from cell culture, animal studies or clinical trials, and our workflows are ideally suited to untargeted comparative analyses.
Australian Translational Medicinal Chemistry Facility: ATMCF is a purpose-designed, outward-facing, collaborative facility that supports early stage medicinal chemistry-led drug discovery. ATMCF provides medicinal chemistry insight and expertise and a translational bridge between early-stage biology and translational lead optimisation and pre-clinical development.
Centre for Drug Candidate Optimisation: CDCO provides expertise and infrastructure in Absorption-Distribution-Metabolism-Excretion (ADME) and pharmacokinetic (PK) profiling during lead optimisation for multidisciplinary drug discovery teams to improve compound design, selection and progression through to drug candidate selection.
The Helen MacPherson Smith (HMS) Trust Laboratory: This open-access analytical facility uses sophisticated physical and chemical characterisation techniques to overcome challenges faced in modern drug development. Academic and industry researchers can access a comprehensive suite of advanced chemical characterisation instruments.
Medicines Manufacturing Innovation Centre (MMIC): MMIC is an initiative established with the Victorian State Government to bring academic and industrial scientists together to optimise manufacturing processes, enhance current and new product development and build a highly skilled, industry ready, workforce. MMIC provides specialist analytical and formulation development services via a team of experienced industrial scientists.
MIPS has significant capability in cryo-EM, NMR and crystallography and the use of this information in structure based drug design. We house an extensive range of ultra-precision microscopes include widefield, high throughput, holographic, hyperspectral, electron, super-resolution, confocal, multiphoton, lifetime imaging and label free confocal. We also provide analytical and sorting flow cytometry (FACS).
Our Therapeutic Program Areas (TPAs)
Our research covers a range of diseases but has a particular focus in three major therapeutic areas